RVTY Quote, Financials, Valuation and Earnings

Azenta has a net margin of 13.8% compared to Revvity's net margin of -2.93%. Revvity's return on equity of 3.24% beat Azenta's return on equity of -7.49%.

Revvity has a consensus price target of $138.47, signalling upside risk potential of 23.26%. On the other hand Azenta has an analysts' consensus of -- which suggests that it could grow by 9.75%. Given that Revvity has higher upside potential than Azenta, analysts believe Revvity is more attractive than Azenta.

Revvity has a beta of 1.027, which suggesting that the stock is 2.691% more volatile than S&P 500. In comparison Azenta has a beta of 1.493, suggesting its more volatile than the S&P 500 by 49.318%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 5.05% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $684M, which are larger than Azenta quarterly revenues of $170.1M. Revvity's net income of $94.4M is higher than Azenta's net income of -$5M. Notably, Revvity's price-to-earnings ratio is 54.36x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 5.09x versus 4.19x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of 13.8% compared to Revvity's net margin of -728.57%. Revvity's return on equity of 3.24% beat Bionano Genomics's return on equity of -158.95%.

Revvity has a consensus price target of $138.47, signalling upside risk potential of 23.26%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 362.96%. Given that Bionano Genomics has higher upside potential than Revvity, analysts believe Bionano Genomics is more attractive than Revvity.

Revvity has a beta of 1.027, which suggesting that the stock is 2.691% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.944%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 5.05% of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $684M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Revvity's net income of $94.4M is higher than Bionano Genomics's net income of -$44.2M. Notably, Revvity's price-to-earnings ratio is 54.36x while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 5.09x versus 0.30x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 13.8% compared to Revvity's net margin of 4.73%. Revvity's return on equity of 3.24% beat Bruker's return on equity of 19.61%.

Revvity has a consensus price target of $138.47, signalling upside risk potential of 23.26%. On the other hand Bruker has an analysts' consensus of $74.01 which suggests that it could grow by 26.92%. Given that Bruker has higher upside potential than Revvity, analysts believe Bruker is more attractive than Revvity.

Revvity has a beta of 1.027, which suggesting that the stock is 2.691% more volatile than S&P 500. In comparison Bruker has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.733%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Bruker offers a yield of 0.34% to investors and pays a quarterly dividend of $0.05 per share. Revvity pays 5.05% of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $684M, which are smaller than Bruker quarterly revenues of $864.4M. Revvity's net income of $94.4M is higher than Bruker's net income of $40.9M. Notably, Revvity's price-to-earnings ratio is 54.36x while Bruker's PE ratio is 28.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 5.09x versus 2.66x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 13.8% compared to Revvity's net margin of -21.86%. Revvity's return on equity of 3.24% beat Harvard Bioscience's return on equity of -20.42%.

Revvity has a consensus price target of $138.47, signalling upside risk potential of 23.26%. On the other hand Harvard Bioscience has an analysts' consensus of -- which suggests that it could grow by 197.62%. Given that Harvard Bioscience has higher upside potential than Revvity, analysts believe Harvard Bioscience is more attractive than Revvity.

Revvity has a beta of 1.027, which suggesting that the stock is 2.691% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.217%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.25%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 5.05% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $684M, which are larger than Harvard Bioscience quarterly revenues of $22M. Revvity's net income of $94.4M is higher than Harvard Bioscience's net income of -$4.8M. Notably, Revvity's price-to-earnings ratio is 54.36x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 5.09x versus 0.93x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.